Innovative Therapy, Monoclonal Antibodies and Beyond

Cytokine and Growth Factor Reviews

Volumn 38, Issue , 2017, Pages 1-9

  Di Nicola, M ^a,b   Apetoh, L ^c   Bellone, M ^d   Colombo, M P ^e   Dotti, G ^f   Ferrone, S ^g   Muscolini, M ^h   Hiscott, J ^h   Anichini, A ^b   Pupa, S M ^b   Braud, F de ^b   Del Vecchio, M ^b  

^a Unit of Immunotherapy and Anticancer Innovative Therapeutics   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Pasteur Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC ANTIGEN RECEPTOR; HLA ANTIGEN; IMMUNE CHECKPOINT BLOCKER; INTERLEUKIN 17; MICRORNA; MONOCLONAL ANTIBODY; ONCOLYTIC VIRUS; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL THERAPY; DRUG TARGETING; EXPERIMENTAL THERAPY; HUMAN; IMMUNOMODULATION; MELANOMA; MICROFLORA; MOLECULARLY TARGETED THERAPY; MYELOID-DERIVED SUPPRESSOR CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; IMMUNOTHERAPY; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 85030847286     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2017.10.002     Document Type: Short Survey

References (77)

1. Pittoni, P., Tripodo, C., Piconese, S., Mauri, G., Parenza, M., Rigoni, A., et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 71 (2011), 5987–5997.
2. Mauri, G., Jachetti, E., Comuzzi, B., Dugo, M., Arioli, I., Miotti, S., et al. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. Oncotarget 7 (2016), 3905–3920.
3. Sangaletti, S., Tripodo, C., Vitali, C., Portararo, P., Guarnotta, C., Casalini, P., et al. Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. Cancer Discov. 4 (2014), 110–129.
4. Berg, R.D., The indigenous gastrointestinal microflora. Trends Microbiol. 4 (1996), 430–435.
5. Sender, R., Fuchs, S., Milo, R., Are we really vastly outnumbered: revisiting the ratio of bacterial to host cells in humans. Cell 164 (2016), 337–340.
6. Patrignani, P., Tacconelli, S., Bruno, A., Gut microbiota, host gene expression, and aging. J. Clin. Gastroenterol. 48:Suppl 1 (2014), S28–S31.
7. Liu, S., da Cunha, A.P., Rezende, R.M., Cialic, R., Wei, Z., Bry, L., et al. The host shapes the gut microbiota via fecal MicroRNA. Cell Host Microbe 19 (2016), 32–43.
8. Noren Hooten, N., Abdelmohsen, K., Gorospe, M., Ejiogu, N., Zonderman, A.B., Evans, M.K., microRNA expression patterns reveal differential expression of target genes with age. PLoS One, 5, 2010, e10724.
9. Belkaid, Y., Hand, T.W., Role of the microbiota in immunity and inflammation. Cell 157 (2014), 121–141.
10. Enzler, T., Gillessen, S., Manis, J.P., Ferguson, D., Fleming, J., Alt, F.W., et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J. Exp. Med. 197 (2003), 1213–1219.
11. Garrett, W.S., Cancer and the microbiota. Science 348 (2015), 80–86.
12. Yoshimoto, S., Loo, T.M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
13. Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
14. Rutkowski, M.R., Stephen, T.L., Svoronos, N., Allegrezza, M.J., Tesone, A.J., Perales-Puchalt, A., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27 (2015), 27–40.
15. Rutkowski, M.R., Conejo-Garcia, J.R., Size does not matter: commensal microorganisms forge tumor-promoting inflammation and anti-tumor immunity. Oncoscience 2 (2015), 239–246.
16. Chesi, M., Robbiani, D.F., Sebag, M., Chng, W.J., Affer, M., Tiedemann, R., et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13 (2008), 167–180.
17. Rajkumar, S.V., Landgren, O., Mateos, M.V., Smoldering multiple myeloma. Blood 125 (2015), 3069–3075.
18. Calcinotto, A., Ponzoni, M., Ria, R., Grioni, M., Cattaneo, E., Villa, I., et al. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. Oncoimmunology, 4, 2015, e1008850.
19. Chesi, M., Matthews, G.M., Garbitt, V.M., Palmer, S.E., Shortt, J., Lefebure, M., et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120 (2012), 376–385.
20. Dhodapkar, K.M., Barbuto, S., Matthews, P., Kukreja, A., Mazumder, A., Vesole, D., et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 112 (2008), 2878–2885.
21. Noonan, K., Marchionni, L., Anderson, J., Pardoll, D., Roodman, G.D., Borrello, I., A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116 (2010), 3554–3563.
22. Prabhala, R.H., Pelluru, D., Fulciniti, M., Prabhala, H.K., Nanjappa, P., Song, W., et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115 (2010), 5385–5392.
23. Prabhala, R.H., Fulciniti, M., Pelluru, D., Rashid, N., Nigroiu, A., Nanjappa, P., et al. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia 30 (2016), 379–389.
24. Schwartz, H.S., Grindey, G.B., Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 33 (1973), 1837–1844.
25. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007), 1050–1059.
26. Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 (2007), 54–61.
27. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15 (2009), 1170–1178.
28. Cai, L.M.T., Yamada, T., Fan, S., Schwab, J.H., Ferrone, C.R., Ferrone, S., HLA class I antigen-processing machinery in cancer. Butterfield, Lisa H., Kaufman, Howard L., Marincola, Francesco M., (eds.) Cancer Immunotherapy Principles and Practice, 2017, Springer Publishing Co., 44–70.
29. Chang, C.C., Ferrone, S., Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol. Immunother. 56 (2007), 227–236.
30. Benitez, R., Godelaine, D., Lopez-Nevot, M.A., Brasseur, F., Jimenez, P., Marchand, M., et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52 (1998), 520–529.
31. Sabbatino, F., Wang, Y., Scognamiglio, G., Favoino, E., Feldman, S.A., Villani, V., et al. Antitumor Activity of BRAF inhibitor and IFNalpha combination in BRAF-mutant melanoma. J. Natl. Cancer Inst., 2016, 2016.
32. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.
33. Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (2017), 409–413.
34. Reichel, J., Chadburn, A., Rubinstein, P.G., Giulino-Roth, L., Tam, W., Liu, Y., et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125 (2015), 1061–1072.
35. Armand, P., Shipp, M.A., Ribrag, V., Michot, J.M., Zinzani, P.L., Kuruvilla, J., et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J. Clin. Oncol., 2016.
36. Dotti, G., Gottschalk, S., Savoldo, B., Brenner, M.K., Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257 (2014), 107–126.
37. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
38. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14 (2008), 1264–1270.
39. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
40. Lamers, C.H., Sleijfer, S., Vulto, A.G., Kruit, W.H., Kliffen, M., Debets, R., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24 (2006), e20–2.
41. Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33 (2015), 1688–1696.
42. O'Rourke, D.M., Nasrallah, M.P., Desai, A., Melenhorst, J.J., Mansfield, K., Morrissette, J.J.D., et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med., 2017, 9.
43. Heczey, A., Louis, C.U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 25 (2017), 2214–2224.
44. Breitbach, C.J., Lichty, B.D., Bell, J.C., Oncolytic viruses: therapeutics with an identity crisis. EBioMedicine 9 (2016), 31–36.
45. Lichty, B.D., Breitbach, C.J., Stojdl, D.F., Bell, J.C., Going viral with cancer immunotherapy. Nat. Rev. Cancer 14 (2014), 559–567.
46. Rehman, H., Silk, A.W., Kane, M.P., Kaufman, H.L., Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J. Immunother. Cancer, 4, 2016, 53.
47. Ottolino-Perry, K., Diallo, J.S., Lichty, B.D., Bell, J.C., McCart, J.A., Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18 (2010), 251–263.
48. Russell, S.J., Peng, K.W., Bell, J.C., Oncolytic virotherapy. Nat. Biotechnol. 30 (2012), 658–670.
49. Russell, S.J., Peng, K.W., Oncolytic virotherapy: a contest between apples and oranges. Mol Ther. 25 (2017), 1107–1116.
50. Nguyen, T.L., Abdelbary, H., Arguello, M., Breitbach, C., Leveille, S., Diallo, J.S., et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 14981–14986.
51. Diallo, J.S., Le Boeuf, F., Lai, F., Cox, J., Vaha-Koskela, M., Abdelbary, H., et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol. Ther. 18 (2010), 1123–1129.
52. Arulanandam, R., Batenchuk, C., Varette, O., Zakaria, C., Garcia, V., Forbes, N.E., et al. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat. Commun., 6, 2015, 6410.
53. Alain, T., Lun, X., Martineau, Y., Sean, P., Pulendran, B., Petroulakis, E., et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 1576–1581.
54. Samuel, S., Beljanski, V., Van Grevenynghe, J., Richards, S., Ben Yebdri, F., He, Z., et al. BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis. Mol Ther. 21 (2013), 1413–1423.
55. Olagnier, D., Lababidi, R.R., Hadj, S.B., Sze, A., Liu, Y., Naidu, S.D., et al. Activation of Nrf2 signaling augments vesicular stomatitis virus oncolysis via autophagy-driven suppression of antiviral immunity. Mol. Ther. 25 (2017), 1900–1916.
56. Shen, W., Patnaik, M.M., Ruiz, A., Russell, S.J., Peng, K.W., Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood 127 (2016), 1449–1458.
57. Chesney, J., Collichio, F., Andtbacka, R.H.I., Puzanov, I., Glaspy, J., Milhem, M., et al. Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma. Ann. Oncol., 2016, 2016.
58. Qiao, J., Wang, H., Kottke, T., Diaz, R.M., Willmon, C., Hudacek, A., et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther. 15 (2008), 604–616.
59. Yan, Y., Li, S., Jia, T., Du, X., Xu, Y., Zhao, Y., et al. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biol. 36 (2015), 4535–4543.
60. Saha, D., Martuza, R.L., Rabkin, S.D., Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell. 32 (2017), 253–267 (e5).
61. Sharma, P., Hu-Lieskovan, S., Wargo, J.A., Primary, Ribas A., Adaptive, and acquired resistance to cancer immunotherapy. Cell 168 (2017), 707–723.
62. Moynihan, K.D., Opel, C.F., Szeto, G.L., Tzeng, A., Zhu, E.F., Engreitz, J.M., et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22 (2016), 1402–1410.
63. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
64. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34.
65. Antonia, S.J., Lopez-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P., et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17 (2016), 883–895.
66. Figueroa-Magalhaes, M.C., Jelovac, D., Connolly, R., Wolff, A.C., Treatment of HER2-positive breast cancer. Breast 23 (2014), 128–136.
67. Sullivan, I., Planchard, D., ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther. Adv. Med. Oncol. 8 (2016), 32–47.
68. Gladfelter, P., Darwish, N.H.E., Mousa, S.A., Current status and future direction in the management of malignant melanoma. Melanoma Res. 27 (2017), 403–410.
69. Bradley, S.D., Chen, Z., Melendez, B., Talukder, A., Khalili, J.S., Rodriguez-Cruz, T., et al. BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. Cancer Immunol. Res. 3 (2015), 602–609.
70. Frederick, D.T., Piris, A., Cogdill, A.P., Cooper, Z.A., Lezcano, C., Ferrone, C.R., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19 (2013), 1225–1231.
71. Ngiow, S.F., Knight, D.A., Ribas, A., McArthur, G.A., Smyth, M.J., BRAF-targeted therapy and immune responses to melanoma. Oncoimmunology, 2, 2013, e24462.
72. Schilling, B., Paschen, A., Immunological consequences of selective BRAF inhibitors in malignant melanoma: neutralization of myeloid-derived suppressor cells. Oncoimmunology, 2, 2013, e25218.
73. Ott, P.A., Bhardwaj, N., Impact of MAPK pathway activation in BRAF(V600) melanoma on T cell and dendritic cell function. Front. Immunol., 4, 2013, 346.
74. Khalili, J.S., Liu, S., Rodriguez-Cruz, T.G., Whittington, M., Wardell, S., Liu, C., et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 18 (2012), 5329–5340.
75. Kumar, K.G., Liu, J., Li, Y., Yu, D., Thomas-Tikhonenko, A., Herlyn, M., et al. Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol. Ther. 6 (2007), 1437–1441.
76. Liu, L., Mayes, P.A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 21 (2015), 1639–1651.
77. Ribas, A., Hodi, F.S., Callahan, M., Konto, C., Wolchok, J., Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368 (2013), 1365–1366.